

Lundberg Elena¹, Andersson Björn¹, Kriström Berit¹, Rosberg Sten² and Albertsson Wikland Kerstin²
Inst of Clinical Sciences, Pediatrics, Umeå University¹, Dep of Physiology/Endocrin, Inst of Neuroscience/physiology²,
The Sahlgrenska Academy at University of Gothenburg,

P3-945

ESPE Barcelona 2015



Aim: to measure the bioavailable immunoreactive GH serum concentration after sc injection in relation to injected GH dose in GH treated children.

Background: The current administration of GH is daily subcutaneous (sc) injection at bedtime. The variation in uptake of injected GH both within and between patients is hardly known.


Conclusion

A great intra and inter-individual variability in GH uptake from sc injection was found.

Results




Material



Study population: 115 patients (92 boys, 23 girls), followed yearly 2-8 times 1992-99.

Study design: GH, Genotropin® pen 4/16, needle 12mm, dose 33 or 67µg/kg/d sc injected at 18.00 by patient, 90 deep sc in thigh. GH serum-sampling every 2ndh until 16h after inj.

Methods



Pharmacokinetics: estimated by T_{max}(h), C_{max}(mU/L), AUC 0-16h above baseline (AUC_{16h}) (mU/L).

GH-assay: analysed by Pharmacia Polyclonal assay, IRP 80-505.